These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35687793)

  • 1. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.
    Visco DM; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2022 Aug; 28(8):892-902. PubMed ID: 35687793
    [No Abstract]   [Full Text] [Related]  

  • 2. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
    Wirta D; Vollmer P; Paauw J; Chiu KH; Henry E; Striffler K; Nau J;
    Ophthalmology; 2022 Apr; 129(4):379-387. PubMed ID: 34767866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
    Sheppard JD; O'Dell LE; Karpecki PM; Raizman MB; Whitley WO; Blemker G; Hemphill M; Hendrix LH; Gibson A; Macsai M
    Optom Vis Sci; 2023 Feb; 100(2):164-169. PubMed ID: 36728653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.
    Hauswirth SG; Kabat AG; Hemphill M; Somaiya K; Hendrix LH; Gibson AA
    J Comp Eff Res; 2023 Jun; 12(6):e220215. PubMed ID: 37096956
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
    Torkildsen GL; Pattar GR; Jerkins G; Striffler K; Nau J
    Clin Ther; 2022 Sep; 44(9):1178-1186. PubMed ID: 35965109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease.
    Katz J; Periman LM; Maiti S; Sarnicola E; Hemphill M; Kabat AG; Hendrix LH; Shah P; Gibson A
    Clin Ther; 2022 Nov; 44(11):1463-1470. PubMed ID: 36763994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study.
    Quiroz-Mercado H; Hernandez-Quintela E; Chiu KH; Henry E; Nau JA
    Ocul Surf; 2022 Apr; 24():15-21. PubMed ID: 34920097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review.
    Ballesteros-Sánchez A; Borroni D; De-Hita-Cantalejo C; Sánchez-González MC; Sanchez-Gomez S; Rocha-de-Lossada C; Sánchez-González JM
    Cont Lens Anterior Eye; 2024 Feb; 47(1):102097. PubMed ID: 38065797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2.
    Schallhorn JM; McGee S; Nau J; Macsai M; Gibson A; Blemker G; Hendrix LH; Massaro-Giordano M
    Clin Ophthalmol; 2023; 17():725-734. PubMed ID: 36895950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease.
    Wirta D; Torkildsen GL; Boehmer B; Hollander DA; Bendert E; Zeng L; Ackermann M; Nau J
    Cornea; 2022 Oct; 41(10):1207-1216. PubMed ID: 36107843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use.
    Epitropoulos AT; Daya SM; Matossian C; Kabat AG; Blemker G; Striffler K; Hendrix L; Macsai M; Gibson A
    Clin Ophthalmol; 2022; 16():3405-3413. PubMed ID: 36249445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial.
    Tian L; Jin X; Wang J; Xu Y; Lu C; Zhao S; Zhu Q; Dai H; Gu H; Zhang M; Wang L; Lu X; Ma L; Zhu L; Zeng Q; Zhang H; Fu Y; Li S; Tao L; Ren Q; Ding F; Zhang S; Zhu S; Li Z; Jie Y
    Lancet Reg Health West Pac; 2024 Apr; 45():101032. PubMed ID: 38440130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
    Sall KN; Cohen SM; Christensen MT; Stein JM
    Eye Contact Lens; 2006 Jan; 32(1):21-6. PubMed ID: 16415689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis.
    Bashrahil B; Taher N; Alzahrani Z; Alnabihi A; Aldahlawi A; Alkhathlan M; Alghamdi S
    BMC Ophthalmol; 2023 Jul; 23(1):319. PubMed ID: 37452334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
    Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
    BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine Amicellar delivery system for dry eyes.
    Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
    Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.